|
All patients
|
Non–metastatic patients (M0)
|
---|
Risk factor
|
HR (95% CI)
|
p-value
|
HR (95% CI)
|
p-value
|
---|
Age
| | | | |
Age<50
|
1.00 (reference)
|
0.029
|
1.00 (reference)
|
0.025
|
Age≥50
|
2.58 (1.10-5.80)
|
6.90 (1.27-37.38)
| |
Gender
| | | | |
Male
|
1.00 (reference)
|
0.759
|
1.00 (reference)
|
0.706
|
Female
|
1.11 (0.57-2.14)
|
1.26 (0.38-5.00)
| |
T stage
| | | | |
T3 + T4
|
1.00 (reference)
|
0.235
|
1.00 (reference)
|
0.381
|
T1 + T2
|
0.65 (0.32-1.33)
|
1.89 (0.45-7.90)
| |
MEN syndrome
| | | | |
Yes
|
1.00 (reference)
|
0.790
|
1.00 (reference)
|
0.374
|
No
|
1.15 (0.41-3.27)
|
2.19 (0.39-12.40)
| |
Genetic status
| | | | |
Known
|
1.00 (reference)
|
0.144
|
1.00 (reference)
|
0.304
|
Unknown
|
2.05 (0.78-5.35)
|
2.48 (0.44-13.96)
| |
Tumor multifocality
| | | | |
Yes
|
1.00 (reference)
|
0.087
|
1.00 (reference)
|
0.222
|
No
|
0.41 (0.15-1.14)
|
0.33 (0.05-1.97)
| |
M stage
| | | | |
M0
|
1.00 (reference)
|
<0.001
|
N/A
|
M1
|
4.74 (2.26-9.95)
|